London & Cambridge, United Kingdom, 3rd February 2022 / Sciad Newswire / Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, and Domainex Ltd., today announce a collaboration focused on developing small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s. Domainex, a leading integrated medicines research services partner, will provide fully integrated drug discovery services including assay biology, medicinal and computational chemistry. The collaboration is anticipated to be undertaken over a two-and-a-half-year period, with Parkinson’s UK investing up to £3 million in the project via its drug development arm – the Parkinson’s Virtual Biotech. The innovative programme is plugging the funding gap to fast-track the projects with the greatest scientific potential to transform the lives of people with Parkinson’s. Leia Mais »
International News
Glaucoma market to grow to $3.5 billion by 2030, driven by launch of new pipeline products, says GlobalData
Steady growth is expected for the glaucoma market across the seven major markets* (7MM) from $2.8 billion in 2020 to $3.5 billion in 2030, at a compound annual growth rate (CAGR) of 2.0%, according to GlobalData. Leia Mais »
Fibre fortification could lower risk of heart disease and diabetes for 7 in 10 UK adults
|
|
Queen’s University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex
Saffron Walden, 26th January 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. The agreement provides an exclusive licence to research, develop, manufacture and commercialise FLIP inhibitors. Domainex has supported the FLIP inhibitor programme from its inception. Leia Mais »
US sickle cell disease market to skyrocket to $4.8bn by 2030, driven by gene therapies and new first-in-class products, says GlobalData
A number of exciting new sickle cell disease (SCD) drugs are set to hit the US market, says GlobalData, including gene therapies that could offer patients a cure. The leading data and analytics company notes that one of the gene therapies that is currently closest to entering the market— bluebird bio’s bb1111—is projected to represent over a quarter of total sales within the space by 2030. Meanwhile, Droxia, a drug that once was the only approved drug for 20 years, will be drowned out by the newcomers. Leia Mais »
Clasado Biosciences announces new HCP learning event for March 2022
Clasado Biosciences (‘Clasado’), a global leader in the development of clinically proven prebiotic ingredient and product solutions for the human gut microbiome, has revealed details of a new learning event for healthcare professionals. Leia Mais »
US sees 18.3% increase of drug price per year, according to GlobalData
The average price of branded drugs in the US has increased by a whopping 18.3%* per year, according to research by GlobalData. As patients are hit by yet another price hike in 2022—434 branded drugs in the US saw a price increase on 1 January by an average of 5.2%, according to GoodRx—the leading data and analytics company notes that this trend is the complete opposite to what is occurring in other major pharmaceutical markets worldwide. Leia Mais »
Pediatric eosinophilic esophagitis needs more treatment options in US, finds GlobalData
Limited treatment options for pediatric patients in the US remain a significant unmet need in the eosinophilic esophagitis (EoE) space, providing an opportunity for developers to expand the current clinical studies to pediatric populations, finds GlobalData, a leading data and analytics company. Leia Mais »
Mario Torchia is the new InSilicoTrials’ Vice President of Sales & Marketing
18 January 2022 – InSilicoTrials, a leader in simulation software solutions for healthcare, announced today his appointment. Torchia gained 15 years of experience in the tech industry, working in multinational companies such as Dassault Systèmes and Siemens.
Most recently he led the Sales Strategy as Delmia Geo Leader for South Europe at Dassault Systèmes, actively supporting customers in their business transformation journey. Leia Mais »
Psoriasis development criteria more competitive than ever, says GlobalData
The psoriasis (PsO) market has typically been dominated by injectable biologics. However, this segment has become fairly saturated, given the number of different efficacious biologics already available. As a result, drug manufacturers now have no choice but to continue setting and exceeding increasingly high clinical development standards to gain a foothold in this mature field, as noted by key opinion leaders (KOLs) interviewed by GlobalData, a leading data and analytics company. Leia Mais »